Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Elicera Therapeutics: BioStock: Green light to continue Elicera's CARMA-trial in B-cell lymphoma

Elicera Therapeutics

Elicera Therapeutics has received the green light from the Data Safety and Monitoring Board (DSMB) to continue its phase I/IIa clinical trial, CARMA, evaluating the CAR T-cell therapy candidate ELC-301 for B-cell lymphoma. Armed with immune-activating properties via the company's iTANK platform, the therapy is a key component of Elicera's broader immunotherapy strategy. The approval comes as the company prepares to present preliminary efficacy data from the first patient cohort in May.

Read the article at biostock.se:

https://www.biostock.se/en/2025/04/green-light-to-continue-eliceras-carma-trial-in-b-cell-lymphoma/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.